pentostatin + bendamustine + ofatumumab

The PBO regimen is a Phase 1 combination therapy consisting of pentostatin, bendamustine, and ofatumumab, developed for the treatment of previously treated chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL). Pentostatin (Nipent) is a small molecule adenosine deaminase (ADA) inhibitor that prevents the deamination of adenosine and deoxyadenosine, leading to the accumulation of dATP and subsequent inhibition of DNA synthesis, particularly in lymphocytes. Bendamustine is a unique cytotoxic agent with both alkylating and antimetabolite properties, causing intra-strand and inter-strand DNA cross-links. Ofatumumab (Arzerra) is a human IgG1 monoclonal antibody that binds to a specific epitope on the CD20 molecule, inducing B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This trial, sponsored by the Sidney Kimmel Cancer Center at Thomas Jefferson University, evaluates the safety and optimal dosing of this synergistic triplet combination.

Other names

Pentostatin, Bendamustine and Ofatumumab